Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Role of Perioperative Dexmedetomidine on Intraoperative Hemodynamics and Neuro-endocrine Response in Patients Undergoing Robot-Assisted Gynecological Surgery

15 novembre 2026 aggiornato da: Ain Shams University

The aim of this study is to evaluate role of perioperative Dexmedetomidine on intraoperative hemodynamics and neuro-endocrine response in patients undergoing Robot-Assisted gynecological surgery.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

The aim of this study is to evaluate role of perioperative Dexmedetomidine on intraoperative hemodynamics and neuro-endocrine response in patients undergoing Robot-Assisted gynecological surgery.

  1. Pre-operative settings:

    Preoperative evaluation of full medical history, laboratory investigations in form of complete blood count, blood sugar, liver function tests, kidney function tests, serum electrolytes and coagulation profile and for fulfilling inclusion criteria. Patients will be trained how to use visual analogue scale (VAS).

    Patients will be divided into two groups:

    Group D :(n = 25) will receive (1 μg/kg) of dexmedetomidine as a loading intravenously for 10 min before anesthesia induction and will be continuously infused at 0.2 μg/kg/h intraoperatively.

    Group P: (n = 25) will receive The same volume of normal saline in the same manner to group D.

  2. Intraoperative Settings:

All patients will receive the standard technique of general anesthesia by the supervisors of the research. Two intravenous wide pore accesses will be secured, one for routine fluids and the other exclusively for Dex. All the patients will receive pantoprazole 40 mg and Ondansetron 4mg intravenously 15 min before induction and Loading dose of Dex infusion 1 mcg/kg will be started and continued for 10 minutes for group D and Normal saline with the same volume will be given to group P in the same manner.

ECG, non-invasive blood pressure and pulse oximeter will be established upon the patient's arrival in the operating room. Induction of anesthesia in both groups will be done by intravenous 1-2 mg/kg propofol, 1mic/kg fentanyl and 0.5 mg/kg atracurium.

Maintenance will be achieved with appropriate sized cuffed endotracheal tube passed orally, and the placement will be confirmed with auscultation and end-tidal carbon dioxide (EtCO2) reading. Anesthesia will be maintained with air and oxygen mixture (60:40), and isoflurane, using a closed circuit , top-up doses of atracurium , and the rate of Dex infusion will be changed to a maintenance infusion of 0.2 mcg/kg/h for group D and the same with normal saline for group P. End-tidal concentration of isoflurane will be monitored by measuring the average concentration and its total dosage through the infrared multi-gas analyzers. Vasopressor response to laryngoscopy and intubation will be documented by noting HR and BP. The lungs will be ventilated by maintaining a tidal volume of 6-8 ml/kg, and a respiratory rate to keep ETCO2 at 35-40 mmHg with continuous monitoring.

Intra-operative bradycardia (pulse rate <50) will be treated with atropine 0.6 mg.

Intra-operative hypotension will be treated with intravenous crystalloids and by reducing the isoflurane concentration and ephedrine. An increase in HR and/or mean arterial pressure (MAP) >20% from baseline values will be treated by 1 mcg/kg of intravenous fentanyl. If there will be no response within 5 min, the initial isoflurane concentration will be increased by 0.2% increment every 4 min up to a maximum of 1% end-tidal concentration. Any additional requirement of lapetalol or nitroglycerine to control BP will be noted Isoflurane inhalation will be stopped 10 min before the end of surgery and dexmedetomidine will be stopped at the end of skin incision closure. The total amount of fentanyl administered during each case will be also recorded.

Blood samples will be analyzed for blood Serum cortisol level, serum glucose and serum lactate.

Serum cortisol level preoperatively (baseline), just after incision, at 6 h after anesthesia induction, at 12 h after induction and at 24 h after induction.

Serum glucose level preoperatively (baseline), just after incision and at 6 h after anesthesia induction.

Serum lactate level preoperatively (baseline), just after incision, at 6 h after anesthesia induction and at 12 h after induction.

  1. Hemodynamic monitoring:

    Intraoperative monitoring was documented during the pre-induction, after the loading dose of Dex, at the induction of anesthesia, during laryngoscopy and intubation, and at pneumoperitoneum and then every 30 min till the end of surgery and continued during extubation and post operatively for 1 hr every 30 min.

  2. Assessment of post-operative pain & sedation:

By the end of surgery, anesthesia will be discontinued and reversal will be given (when full muscle power regained) as neostigmine 0.05 mg/kg and atropine 0.02 mg/kg. Extubation will be done, and the patient will be transferred to the PACU.

Tipo di studio

Interventistico

Iscrizione (Stimato)

50

Fase

  • Fase 4

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

  • Nome: Hala said Hassan, MD
  • Numero di telefono: +201147784179

Luoghi di studio

    • Abbassia, Egypt
      • Cairo, Abbassia, Egypt, Egitto
        • Reclutamento
        • Ain Shams University
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 21 anni a 60 anni (Adulto)

Accetta volontari sani

No

Sessi ammissibili allo studio

Femmina

Descrizione

Inclusion Criteria:

  • Patients aged from 21-60 years.
  • Patients ASA I or II undergoing elective Robot-Assisted gynecological surgery under general anesthesia.

Exclusion Criteria:

  • Patient refusal.
  • ASA III and ASA IV.
  • A known history of allergy to the drugs used.
  • Patients on chronic steroid therapy.
  • Patient with cardiovascular disorder (Bradycardia, heart block, heart failure).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Triplicare

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Group D (Dexmedetomidine)

Receives IV dexmedetomidine loading dose (1 μg/kg over 10 minutes before anesthesia induction) followed by a continuous infusion (0.2 μg/kg/h) until 15 minutes before the end of surgery.

IV loading dose of 1 μg/kg over 10 min prior to induction, then maintenance infusion of 0.2 μg/kg/h until 15 min prior to surgery end.

Comparatore placebo: Group P (Placebo)

Receives normal saline in the same volume and infusion rate schedule as Group D (loading dose over 10 minutes before induction, followed by continuous infusion).

Equivalent volume of normal saline solution administered as an IV loading dose and continuous infusion matching the study drug timeline.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Serum Cortisol Level
Lasso di tempo: Baseline (preoperatively), just after skin incision, and at 6 hours, 12 hours, and 24 hours after anesthesia induction.

Evaluation of the perioperative neuro-endocrine stress response by measuring blood serum cortisol levels.

Baseline (preoperatively), just after skin incision, and at 6 hours, 12 hours, and 24 hours after anesthesia induction.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Time to First Rescue Analgesia
Lasso di tempo: Up to 24 hours postoperatively

The time interval between the completion of drug injection and the participant's first post-operative request for pain relief administered when Numerical Pain Distress Scale above 4 as • 0: No pain

  • 1-3: Mild pain
  • 4-6: Moderate pain
  • 7-10: Severe pain
Up to 24 hours postoperatively
Serum Glucose level
Lasso di tempo: Serum glucose: Baseline, just after incision, and 6 hours post-induction.

Blood serum level of glucose to assess metabolic stress.

Serum glucose: Baseline, just after incision, and 6 hours post-induction.
Numerical Pain Distress Scale (NPDS) Score
Lasso di tempo: Upon recovery in PACU and throughout the first 24 hours postoperatively.

Self-reported pain intensity scored on an 11-point scale (0 = No pain to 10 = Unbearable pain).

Higher number means high pain intensity.

Upon recovery in PACU and throughout the first 24 hours postoperatively.
Ramsay Sedation Scale Score
Lasso di tempo: Upon recovery in PACU and during the first 2 hours postoperatively.

Assessment of sedation level scored from 1 (anxious or restless) to 6 (no response to stimulus).

Upon recovery in PACU and during the first 2 hours postoperatively.
Intraoperative Analgesic Consumption
Lasso di tempo: Intraoperatively measured from induction till end of surgery.

Total intraoperative fentanyl consumption.

Intraoperatively measured from induction till end of surgery.
Intraoperative Mean Arterial Pressure (MAP)
Lasso di tempo: Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.

Hemodynamic monitoring to assess stability and vasopressor/anticholinergic response.

Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.
Incidence of Side Effects and Complications
Lasso di tempo: Up to 24 hours postoperatively.

Occurrence of postoperative nausea, vomiting, bradycardia, hypotension, or respiratory depression.

It will be recorded as yes or No .

Up to 24 hours postoperatively.
Lactate Level
Lasso di tempo: Serum lactate: Baseline, just after incision, 6 hours, and 12 hours post-induction.

Blood serum lactate level to assess metabolic stress.

Serum lactate: Baseline, just after incision, 6 hours, and 12 hours post-induction.
Postoperative Analgesic Consumption
Lasso di tempo: through 24 hours postoperatively.

Total postoperative meperidine consumption.

through 24 hours postoperatively.
Intraoperative Anesthetic Consumption
Lasso di tempo: Intraoperatively measured from induction till end of surgery.

Total intraoperative consumption of isoflurane and average end-tidal concentration

Intraoperatively measured from induction till end of surgery.
Intraoperative Heart Rate (HR)
Lasso di tempo: Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.

Hemodynamic monitoring to assess stability and vasopressor/anticholinergic response.

Recorded pre-induction, post-loading dose, at induction, during laryngoscopy/intubation, at pneumoperitoneum, every 15 minutes intraoperatively, at extubation, and every 30 minutes for 1 hour postoperatively.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

10 gennaio 2026

Completamento primario (Stimato)

1 gennaio 2027

Completamento dello studio (Stimato)

1 luglio 2027

Date di iscrizione allo studio

Primo inviato

13 settembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

15 novembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • FMASU MD328/2025

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

Individual participant data will not be publicly shared in an open repository to protect participant privacy. Aggregate data and trial results will be published in a peer-reviewed journal upon study completion.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .